Paracelsus Medizinische Privatuniversität (PMU)

Research & Innovation
Publications

Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.

#2005
#ANTI-CANCER DRUGS

PMU Authors
Roland Reitsamer, Florentia Peintinger, Wolfgang Hitzl

All Authors
Roland Reitsamer, Florentia Peintinger, Eva Prokop, Wolfgang Hitzl

Journal association
ANTI-CANCER DRUGS

Abstract

We are sorry. The full text is not available.

Keywords

TUMORS, WOMEN, CARCINOMA, SURGICAL ADJUVANT BREAST, PREOPERATIVE CHEMOTHERAPY, DOXORUBICIN, B-18